Back to Search
Start Over
Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
- Source :
- Rheumatology (Oxford, England), Rheumatology (United Kingdom), 60(12), 5765-5774. Oxford University Press
- Publication Year :
- 2021
-
Abstract
- Objectives To evaluate the 1-year cost-effectiveness between three different initial treatment strategies in autoantibody-negative RA patients, according to 2010 criteria. Methods For this analysis we selected all RA patients within the intermediate probability stratum of the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial. The tREACH had a treat-to-target approach, aiming for low DAS Results Average quality-adjusted life-years (s.d.), for iMTX, iHCQ and iGCs were respectively 0.71 (0.14), 0.73 (0.14) and 0.71 (0.15). The average total costs (s.d.) for iMTX, iHCQ and iGCs were, respectively, €10 832 (14.763), €11 208 (12.801) and €10 502 (11.973). Healthcare costs were mainly determined by biological costs, which were significantly lower in the iHCQ group compared with iGCs (P Conclusion iHCQ had the lowest healthcare and highest productivity costs, resulting in a non-significant incremental cost-effectiveness ratio. However, iHCQ had the highest chance of being cost-effective at the Dutch willingness-to-pay threshold for healthcare reimbursement. Therefore, we believe that iHCQ is a good alternative to iMTX in autoantibody-negative RA patients, but validation is needed. Clinical trial registration number ISRCTN26791028
- Subjects :
- Male
medicine.medical_specialty
economic evaluation
Cost-Benefit Analysis
autoantigens and autoantibodies
Arthritis, Rheumatoid
QALY
Rheumatology
Internal medicine
medicine
Humans
Pharmacology (medical)
Single-Blind Method
Reimbursement
AcademicSubjects/MED00360
Autoantibodies
Cost–utility analysis
business.industry
worker productivity
Autoantibody
cost-utility analysis
Hydroxychloroquine
Health Care Costs
Clinical Science
Middle Aged
medicine.disease
Clinical trial
Rheumatoid arthritis
Cost utility
Antirheumatic Agents
Presenteeism
healthcare and productivity costs
Female
Quality-Adjusted Life Years
business
RA
medicine.drug
Follow-Up Studies
Subjects
Details
- Language :
- English
- ISSN :
- 14620324
- Volume :
- 60
- Issue :
- 12
- Database :
- OpenAIRE
- Journal :
- Rheumatology (United Kingdom)
- Accession number :
- edsair.doi.dedup.....f6d4c12f878805cf847f756126438dd8